{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:11:34Z","timestamp":1793725894039,"version":"4.6.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.critrevonc.2024.104398","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T11:55:12Z","timestamp":1716810912000},"page":"104398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Safety of immune checkpoint inhibitors: An updated comprehensive disproportionality analysis and meta-analysis"],"prefix":"10.1016","volume":"200","author":[{"given":"Simran","family":"Tyagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7806-9986","authenticated-orcid":false,"given":"Anoop","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.critrevonc.2024.104398_bib1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104398_bib2","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104398_bib3","doi-asserted-by":"crossref","first-page":"0157753","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA \u2013 Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104398_bib4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104398_bib5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.pathol.2020.08.017","article-title":"Pembrolizumab associated sarcoid-like lymphadenopathy mimicking progressive disease in Hodgkin lymphoma","volume":"53","author":"Chau","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.critrevonc.2024.104398_bib6","article-title":"Cardiotoxicity induced by immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019 based on FAERS","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2024.104398_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"Chen","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104398_bib8","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1080\/0284186X.2021.1964699","article-title":"The effects of PD-1\/PD-L1 checkpoint inhibitors on recurrent\/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis","volume":"60","author":"Clarke","year":"2021","journal-title":"Acta Oncol. (Madr.)"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104398_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0272022","article-title":"Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy","volume":"17","author":"Cone","year":"2022","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104398_bib10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"16","key":"10.1016\/j.critrevonc.2024.104398_bib11","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.19.03091","article-title":"Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer","volume":"38","author":"Galsky","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104398_bib12","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1365-2036.2008.03655.x","article-title":"Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury","volume":"27","author":"Garc\u00eda-Cort\u00e9s","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104398_bib13","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"issue":"14","key":"10.1016\/j.critrevonc.2024.104398_bib14","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1\u2013selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104398_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1574886318666230228142856","article-title":"Identification of signal of clindamycin associated renal failure acute: a disproportionality analysis","volume":"19","author":"Javed","year":"2024","journal-title":"Curr. Drug Saf."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104398_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40261-018-0735-0","article-title":"Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS","volume":"39","author":"Ji","year":"2019","journal-title":"Clin. Drug Investig."},{"issue":"33","key":"10.1016\/j.critrevonc.2024.104398_bib17","doi-asserted-by":"crossref","first-page":"11936","DOI":"10.1097\/MD.0000000000011936","article-title":"Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer","volume":"97","author":"Khan","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.critrevonc.2024.104398_bib18","series-title":"Meta-analysis in Clinical Research: Principles and Procedures","author":"Kumar","year":"2023"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104398_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.15336","article-title":"Serious disseminated intravascular coagulation associated with combination therapy of nivolumab and ipilimumab in advanced melanoma","volume":"47","author":"Kuriyama","year":"2020","journal-title":"J. Dermatol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104398_bib20","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1016\/j.jid.2022.04.020","article-title":"Cutaneous toxicities associated with immune checkpoint inhibitors: an observational, pharmacovigilance study","volume":"142","author":"Le","year":"2022","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104398_bib21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3904\/kjim.2016.195","article-title":"An overview of meta-analysis for clinicians","volume":"33","author":"Lee","year":"2018","journal-title":"Kor. J. Intern. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104398_bib22","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3390\/cancers14051145","article-title":"Immune checkpoint inhibitors\u2014associated cardiotoxicity","volume":"14","author":"Li","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2024.104398_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105194","article-title":"Comparative efficacy and safety of PD-1\/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials","volume":"160","author":"Li","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104398_bib24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12885-020-07741-0","article-title":"Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems","volume":"21","author":"Ma","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2024.104398_bib25","article-title":"Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: a case report","volume":"26","author":"Nabeshima","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.critrevonc.2024.104398_bib26","unstructured":"NIH Style Guide, National Institutes of Health, 2022. https:\/\/www.nih.gov\/nih-style-guide\/age accessed on 10th july 2023."},{"key":"10.1016\/j.critrevonc.2024.104398_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953761","article-title":"Safety and efficacy of programmed cell death 1 and programmed death ligand-1 inhibitors in the treatment of cancer: an overview of systematic reviews","volume":"13","author":"Ou","year":"2022","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104398_bib28","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/s41591-022-01933-w","article-title":"Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial","volume":"28","author":"Peters","year":"2022","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104398_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104398_bib30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1620\/tjem.254.275","article-title":"Nephrotoxicity of immune checkpoint inhibitors: a disproportionality analysis from 2013 to 2020","volume":"254","author":"Qu","year":"2021","journal-title":"Tohoku J. Exp. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104398_bib31","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104398_bib32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40264-022-01258-0","article-title":"Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: a scoping review of the global literature","volume":"46","author":"Sartori","year":"2023","journal-title":"Drug Saf."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104398_bib33","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20192347","article-title":"Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer","volume":"40","author":"Shao","year":"2020","journal-title":"Biosci. Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104398_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28671","article-title":"Association of antiviral drugs and their possible mechanisms with DRESS syndrome using data mining algorithms","volume":"95","author":"Sharma","year":"2023","journal-title":"J. Med. Virol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104398_bib35","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104398_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14515","article-title":"Use of aspirin in reduction of mortality of COVID-19 patients: a meta-analysis","volume":"75","author":"Srivastava","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.critrevonc.2024.104398_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174579","article-title":"Use of steroids in COVID-19 patients: a meta-analysis","volume":"914","author":"Thakur","year":"2022","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104398_bib38","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00228-021-03273-z","article-title":"Immune-mediated necrotizing myopathy with pembrolizumab: a specific neuromuscular entity","volume":"78","author":"Trenque","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104398_bib39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4103\/ijnm.IJNM_141_18","article-title":"Immune checkpoint inhibitors (Nivolumab)-induced enterocolitis demonstrated on 18 Fluorine-fluorodeoxyglucose positron emission tomography-computed tomography","volume":"34","author":"Usmani","year":"2019","journal-title":"Indian J. Nucl. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104398_bib40","doi-asserted-by":"crossref","first-page":"9167","DOI":"10.1002\/cam4.5655","article-title":"Hepatic failure associated with immune checkpoint inhibitors: an analysis of the Food and Drug Administration Adverse Event Reporting System database","volume":"12","author":"Xu","year":"2023","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104398_bib41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hon.2743","article-title":"Hematological toxicities in immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019","volume":"38","author":"Ye","year":"2020","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104398_bib42","article-title":"Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: an analysis of FAERS data in the past 15 years","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104398_bib43","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.21037\/apm-20-2011","article-title":"The efficiency and safety of immune checkpoint inhibitors in the treatment of small cell lung cancer: a meta-analysis","volume":"9","author":"Zhang","year":"2020","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.critrevonc.2024.104398_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"eClinicalMedicine"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T22:13:29Z","timestamp":1720908809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824001410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":44,"alternative-id":["S1040842824001410"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104398","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of immune checkpoint inhibitors: An updated comprehensive disproportionality analysis and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104398","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104398"}}